ISTH 2022 – Sanofi faces more fitusiran doubts
An investigator asks whether the haemophilia project, which has already been linked with toxicity concerns, should be given to elderly patients.
Key data catalysts for the industry’s small players
Intercept looks for redemption in Nash in the third quarter, while Kymera, Zealand and Anavex hope for share price boosts.
Big pharma’s key third-quarter data
GSK takes on arthritis and Roche aims for convenience, while Pfizer is set to report infant pneumococcal vaccine data.
Covid vaccine development could go Omicron-and-on
Omicron-adapted boosters look good ahead of a key FDA panel, but will the virus soon outmanoeuvre them?
